The search term 'LEUKEMIA' revealed the following 23 open trials:
Trial Number: 06151 | Study Title: Molecular and Biochemical Analysis of Preleukemic and Leukemic Blood Cells from Children with Juvenile Myelomonocytic Leukemia and/or Other Myeloproliferative Disorders, Including Monosomy 7 |
Trial Number: 07082 | Study Title: Fallon, Nevada Leukemia Cluster: An Integrative Study |
Trial Number: AALL08B1 | Study Title: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
Trial Number: 08252 | Study Title: A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients with Refractory or Advanced Chronic Myelogenous Leukemia and other Hematologic Malignancies |
Trial Number: TACL 2009-007 | Study Title: A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered with Re-induction Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) [IND 108753] |
Trial Number: 01151 | Study Title: Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children with Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases |
Trial Number: 082516 | Study Title: A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients with Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation |
Trial Number: AAML0523-CIRB | Study Title: A Phase I/II Study of CLOLAR (Clofarabine, IND# 73, 789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia |
Trial Number: TACL 2005-003 | Study Title: A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia |
Trial Number: 04152 | Study Title: Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children with Stem Cell Defects, Marrow Failure Syndromes, or MDS/Leukemia |
Trial Number: AAML07P1-CIRB | Study Title: A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND# 58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia |
Trial Number: 09255 | Study Title: Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD Activating Mutations |
Trial Number: AALL07P1-CIRB | Study Title: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) |
Trial Number: BMT CTN 0501 | Study Title: Multi-Center, Open Label, Randomized Trial Comparing Single versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia |
Trial Number: AALL0434-CIRB | Study Title: Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia |
Trial Number: 072521 | Study Title: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML) |
Trial Number: AAML0631-CIRB | Study Title: Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND# 103,331) during Consolidation |
Trial Number: AAML0431-CIRB | Study Title: The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years |
Trial Number: AALL0433-CIRB | Study Title: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies |
Trial Number: AALL0631-CIRB | Study Title: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807) |
Trial Number: CALGB 10603-CIRB | Study Title: A Phase III, Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND# 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) |
Trial Number: AALL08P1-CIRB | Study Title: Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study |
Trial Number: AALL02P2 | Study Title: Treatment of Late Isolated Extramedullary Relapsed from Acute Lymphoblastic Leukemia (ALL) (Initial CR1 >/=18 months)
|
